Mark A. Goldsmith Salary and Compensation - Revolution Medicines, Inc. CEO Pay 2024

In fiscal year 2024, Mark A. Goldsmith, President and Chief Executive Officer of Revolution Medicines, Inc. (RVMD), received total compensation of $10.1 million.

Mark A. Goldsmith's compensation breakdown includes: base salary of $689K, stock awards valued at $2.7 million, option awards of $6.0 million, non-equity incentive compensation of $652K, and other compensation of $7K.

Compared to fiscal year 2023, Mark A. Goldsmith's total compensation decreased 3% from $10.4 million to $10.1 million.

Revolution Medicines, Inc. (RVMD) Executive Pay 2024

Revolution Medicines, Inc.'s top 5 named executive officers received combined total compensation of $27.3 million in fiscal year 2024.

The named executive officers disclosed in Revolution Medicines, Inc.'s 2024 proxy statement are:Mark A. Goldsmith (President and Chief Executive Officer) with total compensation of $10.1 million, Steve Kelsey (President Research and Development) with total compensation of $5.9 million, Margaret Horn (Chief Operating Officer) with total compensation of $4.9 million, Jack Anders (Chief Financial Officer) with total compensation of $3.3 million, and Xiaolin Wang (Executive Vice President Development) with total compensation of $3.1 million.